Although current first-line pharmacotherapies—such as levodopa and MAO-B inhibitors—are effective in alleviating motor symptoms, their long-term use is associated with complications including motor fluctuations, “on–off” phenomena, and levodopa-induced dyskinesia. Here, MAOB is linked to drug-induced dyskinesia.